Navigation Links
Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
Date:7/10/2013

DUBLIN, July 10, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/bmljl6/antiviral) has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.

A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed.

Anti-influenza measures applicable to human as well as avian forms are described including the recent epidemic of swine flu. Resistance can develop against neuraminidase inhibitors although it is less than that with adamantanes. Considering these problems, there is need for a more effective agent. Investigations into alternative anti-influenza target will probably expand in the coming years. These include the development of mechanisms to inhibit fusion between the virus envelope and the cell membrane.

After a discussion of current therapies of AIDS/HIV and their limitations, new strategies in development of antiviral agents are described. Drug resistance and toxicities are emerging as major treatment challenges. Based on a review of technologies and drugs in development, it can be stated that there are good prospects are of finding a cure for HIV/AIDS in the next decade.

Hepatitis viruses are described with focus on hepatitis C virus (HCV) and hepatitis B virus (HBV). Despite the presence of numerous drug candidates in the anti-HCV pipeline, and the commitment of major R&D resources by many pharmaceutical companies, it might still take several years for any new anti-HCV drugs to reach the market. Although many companies are focusing their efforts on developing viral inhibitors, cellular targets in the host are beginning to emerge as attractive possibilities because they might enable the development of broad-spectrum antiviral drugs with less chance for developing viral resistance.

Various commercially important viruses include herpes simplex (HSV) and human papilloma virus (HPV). There a number of treatments but HSV is not destroyed completely and remains dormant and activates from time to time to cause various clinical manifestations. There is discussion about the role of HPV in cervical cancer and vaccines available now seem to be adequate in preventing HSV-induced cervical cancer. There is no effective vaccine for respiratory syncytial virus (RSV) although monoclonal antibody (MAb) treatment is useful for prophylaxis and reducing the clinical manifestations. There is a need for an agent to eliminate this virus.

Various viruses that either occur in epidemics or in tropics and some naturally emerging infectious diseases are described, e.g. viral hemorrhagic fevers such as dengue and West Nile virus infection. These are a constant threat and impossible to anticipate. Some of these lack antiviral agents or vaccines for prevention. Although these include some of the most serious viral disorders, the development of antiviral agents for these is not commercially attractive. Current research and approaches to these virus infections are discussed.

Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2012 with projections up to the year 2022.

Profiles of 184 companies that are involved in developing various technologies and products are profiled and with 170 collaborations. These include major pharmaceutical companies (13), Biopharmaceutical companies with antiviral products (82), Antiviral drug companies (26) as well as viral vaccine companies (63). The report is supplemented with 50 tables, 11 figures and 500 references from the literature.

Key Topics Covered:

Executive Summary

1. Introduction to Virology

2. Antiviral Approaches

3. Vaccines for Virus Infections

4. Role of Nanotechnology in Developing Antiviral Agents

5. Delivery of Antivirals

6. Competitive Assessment of Antiviral Approaches

7. Influenza Viruses

8. AIDS/HIV

9. Hepatitis Viruses

10. Miscellaneous Commercially Important Virus Infections

11. Viruses with High Impact but Low Commercial Significance

12. Markets for Antivirals
13. Companies

14. References


For more information visit http://www.researchandmarkets.com/research/bmljl6/antiviral

Source: Jain PharmaBiotech

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Biotechnology



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016  Zymo Research Corp. announced ... new reference materials that help researchers obtain the ... to analyses. The rapid growth of the study ... to have standard methods to improve the reproducibility ... inherently exist at every step of the measurement ...
(Date:5/25/2016)... 2016 Digital Health Dialog, LLC dba ... the US Patent and Trademark Office of U.S. ... processes for electronic opt-­in and processing of discount ... HIPAA compliance and otherwise. Logo - ... "Our technology allows for individuals to opt­-in ...
(Date:5/24/2016)... May 24, 2016 Cirujanos holandeses ... ayudar a los médicos a compartir sus mejores prácticas ... escala mundial. Profesionales médicos de Europa, África, ... apuntado a la aplicación, que combina la transmisión en ... totalmente seguro. Educación   "Imagine un ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... a half of planning the Multiple Pathways of Recovery Conference , CCAR is pleased ... held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... pathways individuals use to get into and sustain their recovery. Pathways of recovery are ...
(Date:5/27/2016)... ... ... Two director-level employees of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... The award recognizes businesswomen who excel in their fields and who have made significant ... Long-Term Services and Supports) Program at Horizon NJ Health and Theresa Ponton, Director of ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path to ... society can control and change. , As nearly 795,000 Americans suffering from a new ... United States. Plus, with an estimated 129,000 of these people dying from stroke, it’s ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after ... 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting ... Open Market Committee (FOMC) dot charts are of interest to the press for their ...
Breaking Medicine News(10 mins):